Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells

Molecules

Volumn 18, Issue 9, 2013, Pages 10132-10145

  Iachininoto, Maria Grazia ^a   Nuzzolo, Eugenia Rosa ^a   Bonanno, Giuseppina ^a   Mariotti, Andrea ^a   Procoli, Annabella ^a   Locatelli, Franco ^b,c   De Cristofaro, Raimondo ^a   Rutella, Sergio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Acute leukaemia; Immune tolerance; Immunotherapy; Indoleamine 2 3 dioxygenase; Interferon ; Regulatory T cells

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; IFNG PROTEIN, HUMAN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INTERFERON RECEPTOR; KYNURENINE; NIMESULIDE; PROSTAGLANDIN E2; PTGS2 PROTEIN, HUMAN; SULFONAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOSYNTHESIS; CELL STRAIN HL 60; COCULTURE; DRUG EFFECT; ENZYME INDUCTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; SECRETION (PROCESS); DRUG EFFECTS; HL 60 CELL LINE;

COCULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; ENZYME INDUCTION; HL-60 CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KYNURENINE; LEUKEMIA, MYELOID, ACUTE; RECEPTORS, INTERFERON; SULFONAMIDES; T-LYMPHOCYTES, REGULATORY;

EID: 84885090543     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules180910132     Document Type: Article

References (41)

1. Munn, D.H.; Mellor, A.L. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013, 34, 137-143.
2. Mellor, A.L.; Munn, D.H. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat. Rev. Immunol. 2004, 4, 762-774. (Pubitemid 39336293)
3. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11, 312-319. (Pubitemid 40460560)
4. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22, 633-642. (Pubitemid 40719198)
5. Takikawa, O.; Kuroiwa, T.; Yamazaki, F.; Kido, R. Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263, 2041-2048. (Pubitemid 18052167)
6. Taylor, M.W.; Feng, G.S. Relationship between interferon- γindoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5, 2516-2522. (Pubitemid 21905800)
7. Byrne, G.I.; Lehmann, L.K.; Kirschbaum, J.G.; Borden, E.C.; Lee, C.M.; Brown, R.R. Induction of tryptophan degradation in vitro and in vivo: a γ-interferon-stimulated activity. J. Interferon Res. 1986, 6, 389-396. (Pubitemid 16003259)
8. Caplen, H.S.; Gupta, S.L. Differential regulation of a cellular gene by human interferon-γ and interferon-γ. J. Biol. Chem. 1988, 263, 332-339. (Pubitemid 18041081)
9. Bonanno, G.; Mariotti, A.; Procoli, A.; Folgiero, V.; Natale, D.; De Rosa, L.; Majolino, I.; Novarese, L.; Rocci, A.; Gambella, M.; et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J. Transl. Med. 2012, 10, 247.
10. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonia, S.J.; Messina, J.L.; Chandler, P.; Koni, P.A.; Mellor, A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 2004, 114, 280-290. (Pubitemid 39071633)
11. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.; Pessina, G.; Pandolfi, S.; Natoni, F.; et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 2006, 108, 218-227. (Pubitemid 43990632)
12. Curti, A.; Aluigi, M.; Pandolfi, S.; Ferri, E.; Isidori, A.; Salvestrini, V.; Durelli, I.; Horenstein, A.L.; Fiore, F.; Massaia, M.; et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007, 21, 353-355. (Pubitemid 46158132)
13. Witkiewicz, A.; Williams, T.; Cozzitorto, J.; Durkan, B.; Showalter, S.; Yeo, C.J.; Brody, J.R. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J. Am. Coll. Surg. 2008, 206, 849-854.
14. Chamuleau, M.E.; van de Loosdrecht, A.A.; Hess, C.J.; Janssen, J.J.; Zevenbergen, A.; Delwel, R.; Valk, P.J.; Lowenberg, B.; Ossenkoppele, G.J. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 2008, 93, 1894-1898.
15. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269-1274. (Pubitemid 37279849)
16. Corm, S.; Berthon, C.; Imbenotte, M.; Biggio, V.; Lhermitte, M.; Dupont, C.; Briche, I.; Quesnel, B. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFNγ. Leuk. Res. 2009, 33, 490-494.
17. Rocca, B.; FitzGerald, G.A. Cyclooxygenases and prostaglandins: shaping up the immune response. Int. Immunopharmacol. 2002, 2, 603-630. (Pubitemid 34246363)
18. Cesario, A.; Rocca, B.; Rutella, S. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr. Med. Chem. 2011, 18, 2263-2271.
19. Nakanishi, M.; Menoret, A.; Tanaka, T.; Miyamoto, S.; Montrose, D.C.; Vella, A.T.; Rosenberg, D.W. Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity. Cancer Prev. Res. 2011, 4, 1198-1208.
20. Wang, D.; Dubois, R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10, 181-193.
21. Wang, D.; Dubois, R.N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 2010, 29, 781-788.
22. Wu, T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim. Biophys. Acta 2005, 1755, 135-150. (Pubitemid 40982563)
23. Vincent, C.; Donnard, M.; Bordessoule, D.; Turlure, P.; Trimoreau, F.; Denizot, Y. Cyclooxygenase-2 (Cox-2) and blast cells of patients with acute leukemia. Leuk. Res. 2008, 32, 671-673. (Pubitemid 351248960)
24. Sharma, S.; Yang, S.C.; Zhu, L.; Reckamp, K.; Gardner, B.; Baratelli, F.; Huang, M.; Batra, R.K.; Dubinett, S.M. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005, 65, 5211-5220. (Pubitemid 40827331)
25. Mukherjee, P.; Basu, G.D.; Tinder, T.L.; Subramani, D.B.; Bradley, J.M.; Arefayene, M.; Skaar, T.; De Petris, G. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 2009, 182, 216-224.
26. Basu, G.D.; Tinder, T.L.; Bradley, J.M.; Tu, T.; Hattrup, C.L.; Pockaj, B.A.; Mukherjee, P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol. 2006, 177, 2391-2402. (Pubitemid 44201000)
27. Platanias, L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5, 375-386. (Pubitemid 40685987)
28. Zaidi, M.R.; Merlino, G. The two faces of interferon-γ in cancer. Clin. Cancer Res. 2011, 17, 6118-6124.
29. Puhlmann, U.; Ziemann, C.; Ruedell, G.; Vorwerk, H.; Schaefer, D.; Langebrake, C.; Schuermann, P.; Creutzig, U.; Reinhardt, D. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. 2005, 312, 346-354. (Pubitemid 40096488)
30. Kudo, Y.; Boyd, C.A. The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J. Physiol. 2001, 531, 417-423. (Pubitemid 32229667)
31. Lee, S.Y.; Choi, H.K.; Lee, K.J.; Jung, J.Y.; Hur, G.Y.; Jung, K.H.; Kim, J.H.; Shin, C.; Shim, J.J.; In, K.H.; et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother. 2009, 32, 22-28.
32. Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057-1061. (Pubitemid 36222930)
33. Beyer, M.; Schultze, J.L. Regulatory T cells in cancer. Blood 2006, 108, 804-811. (Pubitemid 44154611)
34. Shimizu, K.; Nakata, M.; Hirami, Y.; Yukawa, T.; Maeda, A.; Tanemoto, K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 585-590.
35. Malek, T.R.; Bayer, A.L. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004, 4, 665-674. (Pubitemid 39223073)
36. Soliman, H.H.; Antonia, S.J.; Sullivan, D.; Vanahanian, N.; Link, C. Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol. 2009, 27, 3004A.
37. Curti, A.; Pandolfi, S.; Valzasina, B.; Aluigi, M.; Isidori, A.; Ferri, E.; Salvestrini, V.; Bonanno, G.; Rutella, S.; Durelli, I.; et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 into CD25+ T regulatory cells. Blood 2007, 109, 2871-2877. (Pubitemid 46482083)
38. Rutella, S.; Pierelli, L.; Bonanno, G.; Sica, S.; Ameglio, F.; Capoluongo, E.; Mariotti, A.; Scambia, G.; d'Onofrio, G.; Leone, G. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002, 100, 2562-2571.
39. Ustun, C.; Miller, J.S.; Munn, D.H.; Weisdorf, D.J.; Blazar, B.R. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011, 118, 5084-5095.
40. Prendergast, G.C.; Chang, M.Y.; Mandik-Nayak, L.; Metz, R.; Muller, A.J. Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammationassociated diseases. Curr. Med. Chem. 2011, 18, 2257-2262.
41. Muller, A.J.; Sharma, M.D.; Chandler, P.R.; Duhadaway, J.B.; Everhart, M.E.; Johnson, B.A., 3rd; Kahler, D.J.; Pihkala, J.; Soler, A.P.; Munn, D.H.; et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. USA 2008, 105, 17073-17078.